TRICOM + TAXOTERE

泰索帝

• 批准号: 7608288
• 负责人: JOHN L. MARSHALL
• 金额: $ 1.08万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608288
• 关键词: Antitumor Response; Biological Assay; Cells; Colon Carcinoma; Computer Retrieval of Information on Scientific Projects Database; Development; Disease; Dose; End Point; Funding; Grant; Immune response; Immunotherapy; Institution; Lung; Measures; Medical; Numbers; Outcome; Patients; Phase II Clinical Trials; Polymerase Chain Reaction; Population; Rate; Research; Research Personnel; Resources; Reverse Transcriptase Polymerase Chain Reaction; Schedule; Source; Standards of Weights and Measures; T-Lymphocyte; Time; Toxic effect; Tumor Burden; United States National Institutes of Health; cancer immunotherapy; chemotherapy; circulating cancer cell; docetaxel; enzyme linked immunospot assay; experience; improved; response; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objectives: 1)To determine the impact of the varying does and schedules of doctetaxel on CEA-specific T cell immune responses using the ELISPOT assay 2) To determin the recommended dose and schedule for further study as defined by the best immune response with acceptable toxicity 3) To document any objective antitumor response that occurs 4) To determine the impact of treatment on the quantity of circulating CEA cells using quantative real time PCR as an intermediate endpoint Medical Relevance: Patients with advanced metastatic CEA-bearing cancers of the colon or lung have very limited treatment options and those available have not been proven to improve overall survival. This is a population for which new therapies are needed. Cancer immunotherapy and target therapy has made significant advances in the last few years but when given alone they may succeed in stabilization of disease but have limited potential for causing major responses in patients with heavy tumor burden. Exploration of the combination of immunotherapy with chemotherapy is a logical next step to take in furthering the development of new treatment options for this group of patients. Expected Outcome: The endpoints of this trial are: 1) Tumor response measured according to standard RECIST criteria 2) Imune response will be measured by ELISPOT 3) The number of patients experiencing and toxicities will be recorded and the toxicity rate will be determined. 4) The number of circulating cancer cells will be determined by RT-PCR. It is expected that this trial will identify the best combination of terms of disease response, immune response, and toxicity to bring forward into a large Phase II trial.

这个子项目是众多研究子项目之一